Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Celator Pharmaceuticals Inc (CPXX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/12/2016 8-K Quarterly results
06/14/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Celator Pharmaceuticals ® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia"
06/06/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ Significantly Improved Overall Survival — First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk AML— — Data presented at the American Society of Clinical Oncology"
05/31/2016 8-K Form 8-K - Current report
03/23/2016 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and Stifel, Nicolaus & Company, Incorporated, as the Representative of the several underwriters",
"Opinion of Duane Morris LLP",
"CELATOR ® PHARMACEUTICALS ANNOUNCES PRICING OF A $38.0 MILLION PUBLIC OFFERING OF COMMON STOCK EWING, N.J. – Celator Pharmaceuticals, Inc. , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock. The shares of common stock are being offered at a price of $9.50 per share. The gross proceeds to Celator from this offering are expected to be approximately $38.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Celator. The Company has granted the underwriters a 30-day option to purchase an additional 600,000 shares of common stock to cover over-allotments. The offering is expected to close on or ab..."
03/21/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "-- Recently announced statistically significant improvement in overall survival and induction response rate from pivotal Phase 3 trial for VYXEOS in high-risk AML -- -- NDA submission for VYXEOS planned for third quarter of this year -- -- Ended year with $23.3 million cash and cash equivalents; additional $9.8 million net proceeds raised in first quarter 2016 now provides sufficient cash into the second quarter of 2017 -- EWING, N.J., March 21, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. , a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2015. “In 2015, Celator continued to meet ..."
11/08/2013 8-K Other Events
10/04/2013 8-K Submission of Matters to a Vote of Security Holders
09/12/2013 8-K Other Events
08/14/2013 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
06/06/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/03/2013 8-K Appointed a new director
Docs: "Form of Warrant",
"Securities Purchase Agreement among the Company and the purchasers listed therein",
"Registration Rights Agreement among the Company and the investors listed therein",
"CELATOR ® PHARMACEUTICALS RAISES $32.5 MILLION COMPLETING A $39.3 MILLION PRIVATE PLACEMENT FINANCING Proceeds Will Support Phase 3 Study of CPX-351 in Acute Myeloid Leukemia"
04/18/2013 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or W...
03/06/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy